Novartis AG (NYSE:NVS) Receives Average Recommendation of “Hold” from Brokerages

Novartis AG (NYSE:NVSGet Rating) has been assigned a consensus rating of “Hold” from the eighteen analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $90.00.

NVS has been the subject of several research reports. Wolfe Research lowered Novartis from an “outperform” rating to a “market perform” rating in a research report on Monday, May 9th. StockNews.com initiated coverage on Novartis in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Morgan Stanley increased their target price on Novartis from CHF 90 to CHF 94 in a research report on Friday, May 6th. Barclays increased their target price on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. Finally, UBS Group increased their target price on Novartis from CHF 85 to CHF 88 and gave the stock a “neutral” rating in a research report on Wednesday, April 27th.

Hedge funds have recently bought and sold shares of the stock. AHL Investment Management Inc. bought a new position in Novartis during the 4th quarter valued at approximately $25,000. Arlington Partners LLC purchased a new stake in Novartis during the 4th quarter valued at $27,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novartis during the 4th quarter valued at $32,000. Atwood & Palmer Inc. boosted its stake in Novartis by 400.0% during the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company’s stock valued at $33,000 after purchasing an additional 300 shares during the last quarter. Finally, DeDora Capital Inc. purchased a new stake in Novartis during the 1st quarter valued at $34,000. 9.40% of the stock is owned by institutional investors.

NVS opened at $81.51 on Thursday. The business has a 50 day simple moving average of $87.63 and a two-hundred day simple moving average of $86.94. The firm has a market capitalization of $180.35 billion, a price-to-earnings ratio of 7.59, a PEG ratio of 2.37 and a beta of 0.51. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.25 and a quick ratio of 1.01. Novartis has a one year low of $79.09 and a one year high of $95.17.

Novartis (NYSE:NVSGet Rating) last released its quarterly earnings results on Tuesday, April 26th. The company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.44 by $0.02. The business had revenue of $12.53 billion during the quarter, compared to analyst estimates of $12.61 billion. Novartis had a return on equity of 23.16% and a net margin of 46.47%. Novartis’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.52 EPS. As a group, sell-side analysts expect that Novartis will post 6.1 EPS for the current fiscal year.

Novartis Company Profile (Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

See Also

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.